Severe infections in Portuguese patients with rheumatoid arthritis under biologic treatment - a multicenter,

Filipe Oliveira Pinheiro1, Maria Seabra Rato1, Pedro Madureira1

  • 1Serviço de Reumatologia, Centro Hospitalar Universitário de São João.

ARP Rheumatology
|July 8, 2023
PubMed
Abstract

Insights

Biological disease-modifying anti-rheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) carry infectious risks. This study identified predictors of severe infections (SI) in RA patients on bDMARDs, aiding treatment decisions.

Area of Science:

  • Rheumatology
  • Infectious Diseases
  • Pharmacovigilance

Background:

  • Limited understanding of infectious risks associated with different biological disease-modifying anti-rheumatic drugs (bDMARDs) in rheumatoid arthritis (RA).
  • Need to identify predictors of severe infections (SI) in RA patients undergoing bDMARD therapy.

Purpose of the Study:

  • To assess the incidence and types of severe infections (SI) in Portuguese RA patients treated with bDMARDs.
  • To determine predictors of SI in RA patients on bDMARDs.

Main Methods:

  • Retrospective multicenter cohort study using data from the Rheumatic Diseases Portuguese Registry (Reuma.pt).
  • Comparison of RA patients with and without severe infections (SI) requiring hospitalization, parenteral antibiotics, or resulting in death.
  • Logistic regression analysis to identify independent predictors of SI.

Main Results:

  • A total of 3394 RA patients were analyzed; 4.2% experienced severe infections (SI).
  • Independent predictors of SI included chronic kidney disease, asthma, infliximab use, corticosteroid use, interstitial lung disease, prior orthopedic surgery, and higher HAQ/DAS28 scores.
  • Most SIs occurred with the first bDMARD, often leading to treatment discontinuation.

Conclusions:

  • This study provides real-world data on the incidence and types of SI in Portuguese RA patients on bDMARDs.
  • Identified predictors of SI can inform treatment decisions and risk stratification for RA patients on biologics.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
200
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
156
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
155
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38